Central venous catheters were originally introduced as a vascular access for short-term dialysis. At present, double-lumen silastic catheters are the preferred access means for constant use in apheresis. Some groups describe infection rates that are 3.8 % per 1,000 catheter days in subclavian, 6.1 % in jugular, and 15.7 % in femoral vein catheterization [1]. There are also reports that the use of femoral catheters significantly increases the risk of infections and thrombosis [2], so the internal jugular vein should be considered whenever possible. As guidelines for apheresis, the ISFA guidelines published in 2023 and the clinical practice guidelines issued by the Japanese Society for Apheresis in 2021 are available; however, neither provides specific data regarding infection risk. Therefore, according to Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines [3], the usage of non-cuffed catheters imparts a greater risk of infection than do cuffed catheters. Regardless, we should carefully evaluate the symptoms of catheter- related infections [4].